\(-ㅂ-)/♡ try 1ClickFB.com download facebook videos

Dr. Blackwell on Neratinib in HER2+ Breast Cancer

Say and pronounce Dr. Blackwell On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Kimberly L. Blackwell, MD, medical oncologist at Duke Cancer Institute, discusses the FDA approval of the small molecular inhibitor neratinib for the treatment of ...

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Neratinib in HER2+ Breast Cancer   Extended Adjuvant Therapy for HER2-Positive Breast Cancer   Pending FDA Approval of Neratinib in HER2+ Breast Cancer   Brain Metastases in HER2-Positive Breast Cancer   Treating HER2+ Metastatic Breast Cancer   HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer   Dr. Freedman on Neratinib Plus Capecitabine for CNS Disease from HER2-Positive Breast Cancer   Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer   Extended Adjuvant Therapy for HER2+ Early Breast Cancer   ALTTO Trials Findings For Treating HER2+ Breast Cancer - Mayo Clinic   Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer   Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer   Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer   Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer   Frontline Treatment of ER-Positive Breast Cancer   Dr. Janni on the Benefits of Targeted Therapies for HER2+ Breast Cancer   FDA Approval of Ribociclib for Metastatic Breast Cancer   Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer   Triple-Positive Metastatic Breast Cancer   Study Finds HER2 Breast Cancer Driver In 3 Percent Of Lung Cancers   Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer   Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer   HER2 Testing in Metastatic Breast Cancer   Dr. White on CNS Metastases in HER2+ Breast Cancer   Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment   Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer   Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer   Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer   Dr. Osborne on Pertuzumab in HER2+ Breast Cancer   Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer   Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer   Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer   Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer   First-Line Patient Selection for CDK Inhibitor Use   Biosimilar Trastuzumab   Role of Lapatinib in HER2-Positive Breast Cancer   Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer   Dr. Muss on Determining Treatments for HER2+ Breast Cancer   Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer   Hollis Youngner's Story - Mayo Clinic Model of Care   Recent FDA Approval of Ribociclib as Upfront Therapy   Dr. Chan on ExteNET Trial for HER2+ Breast Cancer   Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer   Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer   Dr. Gradishar Discusses Trastuzumab in HER2+ Breast Cancer   Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer   Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer   Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer   Breast Cancer: Genomic Testing   Dr. Hudis on Neoadjuvant Treatment of HER2-Positive Breast Cancer   Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer   Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer   Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer   Dr. Freedman Discusses CNS Metastases in HER2+ Breast Cancer   Future Treatments of Triple-Negative Breast Cancer   Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer   Dr. Muss on Adjuvant Therapy for Elder Breast Cancer Patients   Dr. Muss on Adjuvant Therapy for Elder Patients with Breast Cancer   Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer   Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer   Comparison of Prognostic Tests in Breast Cancer   CDK Inhibitors in Metastatic Hormone-Driven Breast Cancer   Treatment of Metastatic Breast Cancer With Taxanes   The FDA Just Approved This New treatment For Metastatic Breast Cancers   Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer   Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer   Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer   Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer   Living Healthy: Left Breast Cancer Treatment   Did cellphone cause woman's breast cancer?   Treating Low-Risk HER2-Positive Breast Cancer   PI3K Inhibitors in HR+ Metastatic Breast Cancer   Identifying Genes That Can Predict if Breast Cancer Drug Is Working - Mayo Clinic

Popular Today